Cargando…
Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine
Aplidine, dehydrodidemnin B, is a marine depsipeptide isolated from the Mediterranean tunicate Aplidium albicans currently in phase II clinical trial. In human Molt-4 leukaemia cells Aplidine was found to be cytotoxic at nanomolar concentrations and to induce both a G(1) arrest and a G(2) blockade....
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375382/ https://www.ncbi.nlm.nih.gov/pubmed/11986788 http://dx.doi.org/10.1038/sj.bjc.6600265 |
_version_ | 1782154643294388224 |
---|---|
author | Erba, E Bassano, L Di Liberti, G Muradore, I Chiorino, G Ubezio, P Vignati, S Codegoni, A Desiderio, M A Faircloth, G Jimeno, J D'Incalci, M |
author_facet | Erba, E Bassano, L Di Liberti, G Muradore, I Chiorino, G Ubezio, P Vignati, S Codegoni, A Desiderio, M A Faircloth, G Jimeno, J D'Incalci, M |
author_sort | Erba, E |
collection | PubMed |
description | Aplidine, dehydrodidemnin B, is a marine depsipeptide isolated from the Mediterranean tunicate Aplidium albicans currently in phase II clinical trial. In human Molt-4 leukaemia cells Aplidine was found to be cytotoxic at nanomolar concentrations and to induce both a G(1) arrest and a G(2) blockade. The drug-induced cell cycle perturbations and subsequent cell death do not appear to be related to macromolecular synthesis (protein, RNA, DNA) since the effects occur at concentrations (e.g. 10 nM) in which macromolecule synthesis was not markedly affected. Ten nM Aplidine for 1 h inhibited ornithine decarboxylase activity, with a subsequently strong decrease in putrescine levels. This finding has questionable relevance since addition of putrescine did not significantly reduce the cell cycle perturbations or the cytotoxicity of Aplidine. The cell cycle perturbations caused by Aplidine were also not due to an effect on the cyclin-dependent kinases. Although the mechanism of action of Aplidine is still unclear, the cell cycle phase perturbations and the rapid induction of apoptosis in Molt-4 cells appear to be due to a mechanism different from that of known anticancer drugs. British Journal of Cancer (2002) 86, 1510–1517. DOI: 10.1038/sj/bjc/6600265 www.bjcancer.com © 2002 Cancer Research UK |
format | Text |
id | pubmed-2375382 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23753822009-09-10 Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine Erba, E Bassano, L Di Liberti, G Muradore, I Chiorino, G Ubezio, P Vignati, S Codegoni, A Desiderio, M A Faircloth, G Jimeno, J D'Incalci, M Br J Cancer Experimental Therapeutics Aplidine, dehydrodidemnin B, is a marine depsipeptide isolated from the Mediterranean tunicate Aplidium albicans currently in phase II clinical trial. In human Molt-4 leukaemia cells Aplidine was found to be cytotoxic at nanomolar concentrations and to induce both a G(1) arrest and a G(2) blockade. The drug-induced cell cycle perturbations and subsequent cell death do not appear to be related to macromolecular synthesis (protein, RNA, DNA) since the effects occur at concentrations (e.g. 10 nM) in which macromolecule synthesis was not markedly affected. Ten nM Aplidine for 1 h inhibited ornithine decarboxylase activity, with a subsequently strong decrease in putrescine levels. This finding has questionable relevance since addition of putrescine did not significantly reduce the cell cycle perturbations or the cytotoxicity of Aplidine. The cell cycle perturbations caused by Aplidine were also not due to an effect on the cyclin-dependent kinases. Although the mechanism of action of Aplidine is still unclear, the cell cycle phase perturbations and the rapid induction of apoptosis in Molt-4 cells appear to be due to a mechanism different from that of known anticancer drugs. British Journal of Cancer (2002) 86, 1510–1517. DOI: 10.1038/sj/bjc/6600265 www.bjcancer.com © 2002 Cancer Research UK Nature Publishing Group 2002-05-06 /pmc/articles/PMC2375382/ /pubmed/11986788 http://dx.doi.org/10.1038/sj.bjc.6600265 Text en Copyright © 2002 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Experimental Therapeutics Erba, E Bassano, L Di Liberti, G Muradore, I Chiorino, G Ubezio, P Vignati, S Codegoni, A Desiderio, M A Faircloth, G Jimeno, J D'Incalci, M Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine |
title | Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine |
title_full | Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine |
title_fullStr | Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine |
title_full_unstemmed | Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine |
title_short | Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine |
title_sort | cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine |
topic | Experimental Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375382/ https://www.ncbi.nlm.nih.gov/pubmed/11986788 http://dx.doi.org/10.1038/sj.bjc.6600265 |
work_keys_str_mv | AT erbae cellcyclephaseperturbationsandapoptosisintumourcellsinducedbyaplidine AT bassanol cellcyclephaseperturbationsandapoptosisintumourcellsinducedbyaplidine AT dilibertig cellcyclephaseperturbationsandapoptosisintumourcellsinducedbyaplidine AT muradorei cellcyclephaseperturbationsandapoptosisintumourcellsinducedbyaplidine AT chiorinog cellcyclephaseperturbationsandapoptosisintumourcellsinducedbyaplidine AT ubeziop cellcyclephaseperturbationsandapoptosisintumourcellsinducedbyaplidine AT vignatis cellcyclephaseperturbationsandapoptosisintumourcellsinducedbyaplidine AT codegonia cellcyclephaseperturbationsandapoptosisintumourcellsinducedbyaplidine AT desiderioma cellcyclephaseperturbationsandapoptosisintumourcellsinducedbyaplidine AT fairclothg cellcyclephaseperturbationsandapoptosisintumourcellsinducedbyaplidine AT jimenoj cellcyclephaseperturbationsandapoptosisintumourcellsinducedbyaplidine AT dincalcim cellcyclephaseperturbationsandapoptosisintumourcellsinducedbyaplidine |